Standardization and validation of assays determining cellular immune responses against influenza

Vaccine

Volumn 28, Issue 19, 2010, Pages 3416-3422

  Gijzen, Karlijn ^a   Liu, Wai Ming ^a   Visontai, Ildikó ^b   Oftung, Fredrik ^c   van der Werf, Sylvie ^d   Korsvold, Gro Ellen ^c   Pronk, Inge ^a   Aaberge, Ingeborg S ^c   Tütto, Anna ^b   Jankovics, Istvan ^b   Jankovics, Mate ^b   Gentleman, Beth ^e   McElhaney, Janet E ^e   Soethout, Ernst C ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cellular immune response; Influenza A; Vaccine efficacy

Indexed keywords

CELL MARKER; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; ARTICLE; ASSAY; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; INFLUENZA; INFLUENZA VIRUS; LABORATORY TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STANDARDIZATION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VALIDATION STUDY;

CYTOKINES; GRANZYMES; HUMANS; IMMUNOASSAY; INFLUENZA VACCINES; INFLUENZA, HUMAN; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77950517982     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.076     Document Type: Article

References (43)

1. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., and McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med 186 6 (1997) 859-865
2. McElhaney J.E., Gravenstein S., Krause P., Hooton J.W., Upshaw C.M., and Drinka P. Assessment of markers of the cell-mediated immune response after influenza virus infection in frail older adults. Clin Diagn Lab Immunol 5 6 (1998) 840-844
3. Boon A.C., Fringuelli E., Graus Y.M., Fouchier R.A., Sintnicolaas K., Iorio A.M., et al. Influenza A virus specific T cell immunity in humans during aging. Virology 299 1 (2002) 100-108
4. McElhaney J.E., Hooton J.W., Hooton N., and Bleackley R.C. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 23 25 (2005) 3294-3300
5. Samdal H.H., Bakke H., Oftung F., Holst J., Haugen I.L., Korsvold G.E., et al. A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants. Hum Vaccin 1 2 (2005) 85-90
6. He X.S., Holmes T.H., Zhang C., Mahmood K., Kemble G.W., Lewis D.B., et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80 23 (2006) 11756-11766
7. Zeman A.M., Holmes T.H., Stamatis S., Tu W., He X.S., Bouvier N., et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 26 2 (2007) 107-115
8. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 309 1 (1983) 13-17
9. Bender B.S., Croghan T., Zhang L., and Small Jr. P.A. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175 4 (1992) 1143-1145
10. Graham M.B., and Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186 12 (1997) 2063-2068
11. Epstein S.L., Lo C.Y., Misplon J.A., and Bennink J.R. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 160 1 (1998) 322-327
12. Seo S.H., Peiris M., and Webster R.G. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8(+) T cells expressing gamma interferon. J Virol 76 10 (2002) 4886-4890
13. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176 10 (2006) 6333-6339
14. McElhaney J.E., Ewen C., Zhou X., Kane K.P., Xie D., Hager W.D., et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27 18 (2009) 2418-2425
15. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15 7 (2008) 1042-1053
16. Welliver T.P., Garofalo R.P., Hosakote Y., Hintz K.H., Avendano L., Sanchez K., et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195 8 (2007) 1126-1136
17. Effros R.B., Doherty P.C., Gerhard W., and Bennink J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 145 3 (1977) 557-568
18. Thomas P.G., Keating R., Hulse-Post D.J., and Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 12 1 (2006) 48-54
19. Heiny A.T., Miotto O., Srinivasan K.N., Khan A.M., Zhang G.L., Brusic V., et al. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS ONE 2 11 (2007) e1190
20. Lee L.Y., Ha do L.A., Simmons C., de J., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 10 (2008) 3478-3490
21. Cinatl Jr. J., Michaelis M., and Doerr H.W. The threat of avian influenza A (H5N1). Part IV: development of vaccines. Med Microbiol Immunol 196 4 (2007) 213-225
22. Chotpitayasunondh T., Thisyakorn U., Pancharoen C., Pepin S., and Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS ONE 3 12 (2008) e4028
23. Radosevic K., Rodriguez A., Mintardjo R., Tax D., Bengtsson K.L., Thompson C., et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 26 29-30 (2008) 3640-3646
24. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 4 (2008) 552-561
25. Adar Y., Singer Y., Levi R., Tzehoval E., Perk S., Banet-Noach C., et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27 15 (2009) 2099-2107
26. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106 10 (2009) 3877-3882
27. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Evaluation of New Vaccines. EMEA/CHMP/VWP/164653/2005, 2006:1-19.
28. World Health Organization. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. WHO Technical Report, Series No. 924[Annex 1], 2004:35-101.
29. Eichelberger M., Golding H., Hess M., Weir J., Subbarao K., Luke C.J., et al. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26 34 (2008) 4299-4303
30. Committee for Medicinal Products for Human Use (CHMP). Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application. EMEA/CPMP/VEG/4717/2003-Rev.1, 2008:1-17.
31. Bakke H., Samdal H.H., Holst J., Oftung F., Haugen I.L., Kristoffersen A.C., et al. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Immunol 63 3 (2006) 223-231
32. Ewen C., Kane K.P., Shostak I., Griebel P.J., Bertram E.M., Watts T.H., et al. A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for Granzyme B. J Immunol Methods 276 1-2 (2003) 89-101
33. ICH Expert Working Group. Validation of Analytical Procedures: Text and Methodology Q2(R1). ICH Harmonised Tripartite Guideline, 1994.
34. Horton H., Thomas E.P., Stucky J.A., Frank I., Moodie Z., Huang Y., et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323 1 (2007) 39-54
35. Maecker H.T., Rinfret A., D'Souza P., Darden J., Roig E., Landry C., et al. Standardization of cytokine flow cytometry assays. BMC Immunol 6 (2005) 13
36. Lam R., Farrell R., Aziz T., Gibbs E., Giovannoni G., Grossberg S., et al. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 336 2 (2008) 113-118
37. European Pharmacopoeia 6.0. Assay of Diptheria Vaccine (Adsorbed). 01/2008:20706;2008.
38. European Pharmacopoeia 6.0. Poliomyelitis Vaccine (Inactivated). 01/2008:0214;2008.
39. European Pharmacopoeia 6.0. Assay of Tetanus Vaccine (Adsorbed). 01/2008:20708;2008.
40. Wood J.M., Gaines-Das R.E., Taylor J., and Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 12 2 (1994) 167-174
41. Stephenson I., Das R.G., Wood J.M., and Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25 20 (2007) 4056-4063
42. Djoba Siawaya J.F., Roberts T., Babb C., Black G., Golakai H.J., Stanley K., et al. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS ONE 3 7 (2008) e2535
43. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47 3 (2008) 401-409